Telesis Bio, Inc. (TBIO)
TBIO Stock Price Chart
Explore Telesis Bio, Inc. interactive price chart. Choose custom timeframes to analyze TBIO price movements and trends.
TBIO Company Profile
Discover essential business fundamentals and corporate details for Telesis Bio, Inc. (TBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
18 Jun 2021
Employees
39.00
Website
https://codexdna.comCEO
Eric Esser
Description
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
TBIO Financial Timeline
Browse a chronological timeline of Telesis Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
Earnings released on 4 Jun 2025
Earnings released on 4 Jun 2025
Earnings released on 28 Mar 2025
Earnings released on 7 Nov 2024
EPS came in at -$3.83 surpassing the estimated -$5.30 by +27.74%, while revenue for the quarter reached $1.57M , missing expectations by -21.70%.
Earnings released on 7 Aug 2024
EPS came in at -$7.03 falling short of the estimated -$4.03 by -74.44%, while revenue for the quarter reached $1.55M , missing expectations by -22.50%.
Earnings released on 9 May 2024
EPS came in at -$99.28 falling short of the estimated -$4.14 by -2.30K%, while revenue for the quarter reached $3.44M , missing expectations by -50.14%.
Stock split effective on 9 May 2024
Shares were split 1 : 18 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Mar 2024
EPS came in at -$4.14 surpassing the estimated -$4.50 by +8.00%, while revenue for the quarter reached $6.98M , missing expectations by -0.33%.
Earnings released on 13 Nov 2023
EPS came in at -$6.65 falling short of the estimated -$5.22 by -27.39%, while revenue for the quarter reached $5.56M , missing expectations by -41.43%.
Earnings released on 10 Aug 2023
EPS came in at -$5.04 falling short of the estimated -$4.86 by -3.70%, while revenue for the quarter reached $8.65M , beating expectations by +0.60%.
Earnings released on 11 May 2023
EPS came in at -$6.65 surpassing the estimated -$6.83 by +2.64%, while revenue for the quarter reached $6.32M , missing expectations by -14.65%.
Earnings released on 21 Mar 2023
EPS came in at -$5.04 surpassing the estimated -$5.76 by +12.50%, while revenue for the quarter reached $9.47M , beating expectations by +27.96%.
Earnings released on 8 Nov 2022
EPS came in at -$0.42 surpassing the estimated -$0.48 by +12.50%, while revenue for the quarter reached $6.68M , missing expectations by -3.26%.
Earnings released on 9 Aug 2022
EPS came in at -$0.50 surpassing the estimated -$0.51 by +1.96%, while revenue for the quarter reached $5.66M , beating expectations by +22.93%.
Earnings released on 11 May 2022
EPS came in at -$0.45 falling short of the estimated -$0.43 by -4.65%, while revenue for the quarter reached $5.64M , beating expectations by +44.51%.
Earnings released on 22 Mar 2022
EPS came in at -$0.43 falling short of the estimated -$0.37 by -16.22%, while revenue for the quarter reached $3.08M , missing expectations by -19.70%.
Earnings released on 9 Nov 2021
EPS came in at -$6.12 falling short of the estimated -$5.04 by -21.43%, while revenue for the quarter reached $2.79M .
Earnings released on 10 Aug 2021
EPS came in at -$19.06 falling short of the estimated -$6.47 by -194.59%, while revenue for the quarter reached $2.85M , missing expectations by -96.07%.
Earnings released on 21 Jun 2021
EPS came in at -$0.34 falling short of the estimated -$0.07 by -385.71%, while revenue for the quarter reached $2.33M , missing expectations by -98.91%.
Earnings released on 25 Feb 2021
EPS came in at -$0.22 surpassing the estimated -$0.24 by +8.33%, while revenue for the quarter reached $1.94M , missing expectations by -96.52%.
Earnings released on 5 Nov 2020
EPS came in at $0.23 surpassing the estimated $0.20 by +15.00%, while revenue for the quarter reached $1.64M , missing expectations by -95.87%.
TBIO Stock Performance
Access detailed TBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.